Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vita Life SciencesASX:VLS 84 3-Year EPS without NRI Growth Rate is 12.00% as of Dec. 2025, which is 3% below its 10-year median of 12.35. GuruFocus rates ASX:VLS with a GF Score™ of 84/100 and a GF Value™ of A$2.50 (Fairly Valued). The stock has 1 warning sign investors should review. Among 789 Drug Manufacturers companies, Vita Life Sciences ranks better than 55.39% on this metric.
During the past 12 months, Vita Life Sciences's average EPS without NRI Growth Rate was 16.50% per year.
During the past 3 years, the average EPS without NRI Growth Rate was 12.00% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 7.70% per year.
During the past 10 years, the average EPS without NRI Growth Rate was 14.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Vita Life Sciences was 83.60% per year. The lowest was -26.30% per year. And the median was 12.35% per year.
Vita Life Sciences (ASX:VLS) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Vita Life Sciences 3-Year EPS without NRI Growth Rate Related Terms
ASX:VLS vs ZTS: 3-Year EPS without NRI Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vita Life Sciences's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vita Life Sciences 3-Year EPS without NRI Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vita Life Sciences's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Vita Life Sciences's 3-Year EPS without NRI Growth Rate falls into.
Vita Life Sciences 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 12.00% mean?
Vita Life Sciences (ASX:VLS) has a 3-Year EPS without NRI Growth Rate of 12.00% as of Dec. 2025. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Vita Life Sciences and its competitors. This is near median its historical median of 12.35. According to the industry distribution chart, Vita Life Sciences ranks #352 out of 789 companies in the Drug Manufacturers industry, placing it in the top 44.6%.
Is Vita Life Sciences' 3-Year EPS without NRI Growth Rate too high?
Vita Life Sciences' current 3-Year EPS without NRI Growth Rate of 12.00% is near median its 10-year median of 12.35. The Drug Manufacturers industry median 3-Year EPS without NRI Growth Rate is 9.60. Vita Life Sciences' value of 12.00% is 25% above this industry median. Based on the distribution chart, Vita Life Sciences ranks #352 out of 789 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Vita Life Sciences has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vita Life Sciences' 3-Year EPS without NRI Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vita Life Sciences ranks #352 out of 789 companies for 3-Year EPS without NRI Growth Rate. This puts Vita Life Sciences in the upper half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 9.60. Vita Life Sciences' value of 12.00% is 25% above this benchmark. While the company's 10-year median is 12.35 vs. the industry median of 9.60, Vita Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Drug Manufacturers company?
The median 3-Year EPS without NRI Growth Rate among Drug Manufacturers companies is 9.60, based on 789 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vita Life Sciences's current 3-Year EPS without NRI Growth Rate of 12.00% is 25% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Vita Life Sciences and its competitors. For the Drug Manufacturers industry, the median 3-Year EPS without NRI Growth Rate is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vita Life Sciences's current 3-Year EPS without NRI Growth Rate is 12.00%, which is near median its own 10-year median of 12.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vita Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Vita Life Sciences (ASX:VLS) is currently considered Fairly Valued. The stock's GF Value™ is A$2.50, compared to a current price of A$2.44 — trading 2.4% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 12.00%, which is near median its 10-year median of 12.35 and 25% above the Drug Manufacturers industry median of 9.60. Vita Life Sciences' overall GF Score™ is 84/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Vita Life Sciences (ASX:VLS), the current 3-Year EPS without NRI Growth Rate is 12.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vita Life Sciences (ASX:VLS) Overvalued in 2026?
Based on GuruFocus' analysis, Vita Life Sciences stock appears to be undervalued.
The current stock price of A$2.44 is trading 2.4% below its estimated GF Value™ of A$2.50.
GuruFocus considers Vita Life Sciences to be Fairly Valued.
Key valuation signals for ASX:VLS:
3-Year EPS without NRI Growth Rate: 12.00% (near median its 10-year median of 12.35)
GF Value™: A$2.50 vs. price of A$2.44 (2.4% below fair value)
Industry Position: 25% above the Drug Manufacturers median (#352 of 789)
No single metric tells the full story. See the ASX:VLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vita Life Sciences Ltd is an Australian-based pharmaceutical and healthcare company involved in formulating, packaging, selling, and distributing vitamins and supplements. It produces a wide range of premium supplements, vitamins, minerals, herbs, and superfoods catered to all age categories and health conditions. The company markets its products through pharmacies and health food stores under the VitaHealth, VitaScience, and Herbs of Gold brands throughout the Asia-Pacific region. Vita Life Sciences has two operating segments: VMS Operational, which generates maximum revenue, and VMS Investments. Geographically, the Group generates maximum revenue from Malaysia and Singapore, and the rest from Australia, and China and Vietnam.
84GF Score
Get the complete analysis for ASX:VLS
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VLS has been successfully added to your 
